Key Insights

Highlights

Success Rate

68% trial completion

Published Results

30 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

14.9%

23 terminated out of 154 trials

Success Rate

68.5%

-18.0% vs benchmark

Late-Stage Pipeline

6%

9 trials in Phase 3/4

Results Transparency

60%

30 of 50 completed with results

Key Signals

30 with results68% success23 terminated

Data Visualizations

Phase Distribution

130Total
Not Applicable (33)
Early P 1 (3)
P 1 (48)
P 2 (37)
P 3 (7)
P 4 (2)

Trial Status

Completed50
Recruiting38
Terminated23
Active Not Recruiting18
Unknown13
Withdrawn8

Trial Success Rate

68.5%

Benchmark: 86.5%

Based on 50 completed trials

Clinical Trials (154)

Showing 20 of 20 trials
NCT06995898Not ApplicableRecruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT07282158Not ApplicableRecruitingPrimary

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT07038369Phase 1Active Not Recruiting

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT04981119Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT02345265Phase 2Active Not Recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

NCT07495124Phase 2Not Yet Recruiting

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

NCT04878094Phase 3Recruiting

A Study of Intra-operative Imaging in Women With Ovarian Cancer

NCT06885424Enrolling By Invitation

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

NCT03180294Phase 2Completed

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT05429970Not ApplicableRecruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

NCT07285044Phase 2Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT04969835Phase 1Recruiting

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT06172478Phase 2Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT04314401Active Not Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT04851119Phase 1Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT01696994Not ApplicableActive Not RecruitingPrimary

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

NCT04562623RecruitingPrimary

Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma

NCT06586957Phase 1Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT06964009Phase 1Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Scroll to load more

Research Network

Activity Timeline